ATAI - Atai Life Sciences announces lock-up extension for over 30% of common stock

atai Life Sciences (ATAI -23.4%) discloses that a group of largest pre-IPO investors representing over 30% of the company’s common stock have voluntarily agreed for renewed lock-up agreements extending the trading restrictions of pre-IPO shares for up to 24 months. Among them is Apeiron Investment Group, the family office of the company's Founder and Chairman, Christian Angermayer, which has agreed to extend the lock-up period for another 24 months for nearly ~17.4% of outstanding common stock. Additionally, certain other largest pre-IPO investors of the German-based company have decided to extend their lock-up restrictions for another 12 months. The updated lock-up agreements cover over 30% of atai’s (NASDAQ:ATAI) common stock in total. The renewed agreements “illustrate the confidence of atai’s key shareholders in atai’s platform and its potential to address the growing mental health crisis,” the company said in a statement. However, atai (ATAI) shares have lost more than a fifth in morning

For further details see:

Atai Life Sciences announces lock-up extension for over 30% of common stock